Table 3.

Hazard ratios and odds ratios according to immune checkpoint inhibitors

	No. of studies	No. of patients	Estimates	95% CI		P‐value
				Lower limit	Upper limit
OS			HR
Ipilimumab	3	225	2.20	1.44	3.35	0.000
Nivolumab	2	132	1.63	0.88	3.03	0.121
Pembrolizumab	2	55	2.49	1.00	6.20	0.051
PFS			HR
Ipilimumab	2	244	1.73	1.25	2.38	0.001
Nivolumab	3	163	1.74	0.95	3.20	0.072
Pembrolizumab	2	55	3.32	1.55	7.11	0.002
ORR			OR
Ipilimumab	2	141	0.16	0.04	0.62	0.008
Nivolumab	4	185	0.44	0.11	1.72	0.239
Pembrolizumab	2	184	0.43	0.06	2.82	0.375
DCR			OR
Ipilimumab	2	141	0.28	0.12	0.66	0.003
Nivolumab	2	132	0.34	0.03	3.48	0.367

CI, confidence interval; DCR, disease control rate; HR, hazard ratio; OR, odds ratio; ORR, objective response rate.